Transcatheter arterial chemoembolization (TACE) is widely accepted as a treatment for patients with hepatocellular carcinoma (HCC) in the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) guidelines. Recently, balloon-occluded TACE (B-TACE) was developed in Japan. Despite the lack of a clear definition, B-TACE is generally defined as the infusion of emulsion of chemotherapeutic agents with lipiodol followed by gelatin particles under the occlusion of feeding arteries by a microballoon catheter, which leads to the dense lipiodol emulsion (LE) accumulation in HCC nodules. This phenomenon cannot be explained only by the prevention of proximal migration and leakage of embolization materials; it further involves causing local changes in the hemodynamics of the surrounding occlusion artery and targeted HCC nodules. Balloon-occluded arterial stump pressure plays an important role in the dense LE accumulation in targeted HCC nodules. Although randomized controlled trials comparing the therapeutic effect and the prognosis of B-TACE to those of the other TACE procedures, such as conventional-TACE and drug-eluting beads TACE, are still lacking, B-TACE is thought to be a promising treatment. The purpose of this review is to summarize the mechanism, therapeutic effect, indication, prognosis and complications of B-TACE. Core tip: Balloon-occluded transcatheter arterial chemoembolization (B-TACE) was recently developed in Japan. Despite the lack of a clear definition, B-TACE is generally defined as the infusion of emulsion of chemotherapeutic agents with lipiodol followed by gelatin particles under the occlusion of feeding arteries by a microballoon catheter. Although randomized controlled trials comparing the therapeutic effect and the prognosis of B-TACE to those of the other TACE procedures are still lacking, B-TACE is thought to be a promising treatment. The purpose of this review is to summarize the mechanism, therapeutic effect, indication, prognosis and complications of B-TACE.
Abstract
Transcatheter arterial chemoembolization (TACE) is widely accepted as a treatment for patients with hepatocellular carcinoma (HCC) in the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) guidelines. Recently, balloon-occluded TACE (B-TACE) was developed in Japan. Despite the lack of a clear definition, B-TACE is generally defined as the infusion of emulsion of chemotherapeutic agents with lipiodol followed by gelatin particles under the occlusion of feeding arteries by a microballoon catheter, which leads to the dense lipiodol emulsion (LE) accumulation in HCC nodules. This phenomenon cannot be explained only by the prevention of proximal migration and leakage of embolization materials; it further involves causing local changes in the hemodynamics of the surrounding occlusion artery and targeted HCC nodules. Balloon-occluded arterial stump pressure plays an important role in the dense LE accumulation in targeted HCC nodules. Although randomized controlled trials comparing the therapeutic effect and the prognosis of B-TACE to those of the other TACE procedures, such as conventional-TACE and drug-eluting beads TACE, are still lacking, B-TACE is thought to be a promising treatment. The purpose of this review is to summarize the mechanism, therapeutic effect, indication, prognosis and complications of B-TACE.
INTRODUCTION
Liver cancer ranks sixth as the common malignant neoplasm and second as the cause of death worldwi de [1] , and hepatocellular carcinoma (HCC) is the most common type of malignant liver tumors [2] . According to the Barcelona Clinic Liver Cancer (BCLC) guidelines, transcatheter arterial chemoembolization (TACE) is an established treatment for patients with HCC in the intermediate stage [3] . The median survival of untreated patients at the intermediate stage, who present with multinodular without vascular invasion or extrahepatic metastasis, performance status 0 and ChildPugh cla ss A or B, is reported to be 16 mo [4, 5] , and TACE prolon gs their overall survival compared to that of a control group [6, 7] . TACE is performed through the injection of single or multiple chemotherapeutic agents after the cathe terization of tumorfeeding arteries, followed by the embolization of the same vessels in order to gain a synergistic effect of cytotoxicity and ischemia [3, 8] . Co nventional-TACE (C-TACE) is defined as the injection of a mixture of anticancer agents with lipiodol followed by embolic materials, such as gelatin particles, calibrated microspheres or polyvinyl alcohol, and drugeluting beads TACE (DEB-TACE) is defined as the infusion of microspheres onto which chemotherapeutic agents is loaded or adsorbed to achieve a sustained in vivo drug release [8, 9] . Recently, balloonoccluded TACE (BTACE), which was first reported by Irie et al [10] , has been developed in Japan. Although it is not mentioned in several gui delines [3, 11, 12] and its clear definition has not been est ablished, it is generally defined as the infusion of emulsion of chemotherapeutic agents with lipiodol followed by gelatin particles under the occlusion of feeding arteries by a microballoon catheter. The occlusion of the feeding arteries result in the dense lipiodol emulsion (LE) accumulation in targeted nodules [10] . The therapeutic ef fect of BTACE was better than that of CTACE according to several previous reports [1315] , although those were retrospective and small in scale. In addition, randomized controlled trials (RCTs) comparing the therapeutic effect and the prognosis of BTACE to those of other TACE procedures are still lacking. Table 1 depicts the key findings of the therapeutic effect and overall survival of BTACE. With this potential limitation in mind, in the present review, we describe the current understanding of the mechanism, therapeu tic effect, indication, overall survival and complications of BTACE.
BALLOON-OCCLUDED TACE PROCEDURE

Microballoon catheters
A 3Fr microballoon catheter was used in the study rep orted by Irie et al [10] . However, it is sometimes difficult to advance a microballoon catheter into the targeted tumorfeeding arteries selectively [16] . Moreover, a 5 or 6Fr guiding catheter was required when we used a 3Fr microballoon catheter for BTACE, which is more invasive than CTACE [16] . Microballoon catheters have improved in recent years, and a 1.8Fr microballoon cat heter (Logos, Piolax, Kanagawa, Japan; or Attendant, Terumo Clinical Supply, Tokyo, Japan) is now available, enabling us to insert the catheter more selectively and more peripherally [16] . We are able to coaxially advanc ed these microballoon catheters through a typical 4Fr parent catheter [16] . The proximal side consists of two ports in these microballoon catheters: the microballoon lumen and the microguidewire lumen, the diameter of which is 0.0170.018 inches [16] .
B-TACE procedure
Although a clear definition of B-TACE has not been established and several details concerning the procedure vary markedly among institutions, we will attempt to briefly describe the main points of B-TACE.
The right femoral artery is punctured under local anesthesia. A 4 or 5Fr parent catheter is then plac ed in the celiac artery (CeA) or superior mesenteric artery (SMA), and angiography is carried out to assess the anatomy of the hepatic artery, tumor stains, the feeding arteries and arteriovenous shunting. In some institutions, conebeam computed tomography (CBCT) and angiographyassisted computed tomography (CT) is performed to diagnose the HCC and evaluate the tumorfeeding arteries. A microballoon catheter is inser ted into the tumorfeeding arteries over the guidewire as selectively as possible. When the selective insertion of the microballoon catheter into the targeted arteries is difficult, such as in patients with tortuous anatomies 12 mL of lipiodol (510 mg/mL); 10 mg of doxorubicin hydrochloride and 2 mg of mitomycin C with 510 ml of lipiodol (510 mg/mL and 12 mg/mL, respectively) [10, 15] . Digital angiography is sometimes useful for checking for the flow of LE droplets outside the target areas. LE is infused until sufficient filling of the targeted nodule, overflow into the intrahepatic collateral arteries or the presence of portal vein visualization is observed. The fragmented gelatin sponge slurry is then injected into of the CeA or SMA, using a microballoon catheter as an anchor might be useful for achieving deep cannulati on with the parent catheter [17] . The tumorfeeding artery is then occluded, and the emulsion of lipiodol and anticancer drugs is infused under radiographic gu idance. The proportion of lipiodol to anticancer drugs was as follow: 70 mg of Miriplatin [18, 19] , which is most commonly used in BTACE, was suspended with 3.5 mL of lipiodol (20 mg/mL); 10 mg of epirubicin [20] with [20] 2016 50 Epirubicin-lipiodol suspension + gelatin particle There was no statistically significant difference between the B-TACE group and the C-TACE group NA Irie et al [15] 2016 28 Doxorubicin, mytomysinlipiodol suspension + gelatin particle TE4 89.3%, TE3 10.7%, TE2 0%, TE1 0%, RR 100%. The local recurrence rates at 1, 3, and 5 yr were 92.4%, 69.9%, and 69.9%, respectively
The 1-, 3-, and 5-yr survival rates were 96.4%, 60.3% and 31.1%, respectively B-TACE was an independent factor for improving both the control rate of the primary nodule and the overall survival rates Asayama et al [32] 2016 29 Miriplatin-lipiodol suspension + gelatin particle TE4 8.6%, TE3 48.6%, TE2 17.1%, TE1 25.7%, RR 57.1%
NA
Ogawa et al [14] 2015 33 Miriplatin-lipiodol suspension + gelatin particle TE4 49.2% NA The percentage of TE4 in B-TACE was significantly higher than that in the C-TACE Minami et al [41] 2015 27 Miriplatin-lipiodol suspension + gelatin particle (epirubicin was used in 3 patients)
Countable HCC (n = 17): TE4 43.8%, TE3 12.5%, TE2 37.5%, TE1 6.3%, RR 56.3%, Uncountable HCC (n = 10): CR 0%, PR 0%, SD 10%, PD 90% NA Arai et al [13] 2014 49 Miriplatin-lipiodol suspension + gelatin particle TE4 55.1%, TE3 38.8%, TE2 4.1%, TE1 2.0%, RR 93.9% NA Ishikawa et al [44] 2014 51 Miriplatin-lipiodol suspension + gelatin particle The local recurrence rates at 6, 12 mo were 11.1 %, 26.2%, respectively. The medan recurrence time was 9 mo NA The CT value just after B-TACE was a predictive factor for the tumor response
According to Response Evaluation Criteria in Cancer of the Liver (RECICL), the treatment effect (TE) was defined as follows: TE4, tumor necrosis of 100% or 100% reduction; TE3, tumor necrosis of 50%-100% or 50%-100% reduction in tumor size; TE1, tumor enlargement of > 50% regardless of necrosis; TE2, effect other than TE3 or TE1. the blood vessels until the distal vessel is embolized. We describe a typical BTACE procedure in Figures 13.
MECHANISM OF B-TACE
Irie et al [10] reported that they found dense lipiodol em ulsion (LE) accumulation in HCC nodules when they us ed a 3Fr microballoon catheter in selective TACE with occlusion of feeding arteries. Denser LE accumulation in targeted HCC nodules means more accumulation of anticancer drugs, leading to more therapeutic effect [21, 22] . Therefore, revealing this mechanism is important for he patologists and interventional radiologists in daily clinical practice.
Relationship between the balloon-occluded arterial stump pressure and the dense LE accumulation
The dense LE accumulation caused by the occlusion of feeding arteries cannot be explained only by the prevention of proximal migration and leakage of em bolization materials; it also involves causing local cha nges in the hemodynamics of the surrounding occlusion artery and targeted tumors. Irie et al [10] reported that the pulsatile movement of LE droplets was observed after the inflation of the tip of a balloon catheter, with the peripheral arterial blood flow unable to be stopped. Because stasis of an LE droplet was observed even at the tip of the microballoon catheter, the authors spec ulated that the distal arterial blood flow did not come from leakage though the space between the balloon and the occluded artery. The intrahepatic collateral arteries, such as the peribiliary plexus [23] , interlobar communicating arcade [24] and isolated artery [25] , were considered to help maintain the distal arterial blood flow, based on the observation of anastomotic vessels with collateral arteries on digital subtraction angiograp hy (DSA) under occlusion [10] . Consequently, the BOASP is reduced compared to the mean arterial pressure without balloon occlusion and more decreased BOASP allows the injection of LE under higher pressure. He 
A B C
also demonstrated that BOASP is responsible for the dense LE accumulation and the BOASP ≥ 64 mmHg is predictive for the presence of thick collateral arteries and less dense LE accumulation [10] . Matsumoto et al [26] reported that they used a 1.8Fr microballoon catheter and measured the BOASP at ea ch lobar, segmental and subsegmental arteries before BTACE treatment. He showed that the BOASP ≥ 64 mmHg was founded at A1, A4, A8, anterior segment ar tery, right hepatic artery (RHA) and left hepatic artery (LHA) whereas the BOASP ≥ 64 mmHg was never seen at the other segmental and subsegmental arteries and the BOASP was independent of the size and number of tumors [26] . He presumed that this result was affected by the presence of intrahepatic collateral arteries, es pecially the communicating arcade in the hilum which is a relatively thick anastomosis between the right and left hepatic arteries and originates mainly from A4 and from anterior segment artery or the right hepatic artery [24, 26] . BOASP ≥ 64 mmHg at A1 artery could be explained by the studies reported by Miyayama et al [27, 28] in which the right branch of the communicating artery in the hilum might have been A1 [26] . So, BTACE treatment in A1, A4, A8, anterior segment artery, RHA and LHA possibly caused less dense LE accumulation in targeted HCC nodules [26] . However, this study is small sample size in measured hepatic arteries and lack of the statistical analysis. A large number of validation studies are needed.
Kakuta et al [29] examined the changes in the stump pressure with and without balloon occlusion as well as after BTACE treatment. The mean blood pressure at the targeted occluded artery was 97 mmHg before balloon occlusion and decreased to 49.1 mmHg immediately af ter balloon occlusion, with a statistically significance [29] . Five minutes after balloon occlusion, the mean blood pressure was 50.4 mmHg, and the maintenance of a decreased blood pressure was observed [29] . After the injection of LE and gelatin sponge particles, the mean blood pressure increased to 70.6 mmHg, which was si gnificantly higher than that immediately after balloon occlusion (P < 0.001) [29] . The mean arterial blood pr essure without balloon occlusion after BTACE was not si gnificantly different from that without balloon occlusion before BTACE (P = 0.9107) [29] . Although no significant differences were observed among the stump pressu res at the first-, second-and third-order branches, the proportion of stump pressure < 64 mmHg at third order branches tended to be higher than that at firstor secondorder branches [29] . Advancing a microballoon catheter to a more peripheral artery appeared to cau se the stump pressure to decrease more [29] . A further investigation is needed to determine whether or not the occlusion of a more distal artery results in a more de Although these previous studies [10, 26, 29] have provid ed only preliminary and limited data, the findings indicate that the BOASP plays an important role in the dense LE accumulation in targeted HCC nodules. Further st udies regarding whether or not the BOSAP can predict the longterm therapeutic effect should be conducted.
Hemodynamic changes assessed by CBCT and angioassisted CT
Three reports [3032] have explored the hemodynamic ch anges assessed by balloon occlusion using CBCT and angiography-assisted CT. Ishikawa et al [30] reported that the CBCT pixel values of tumor enhancement increased after balloon occlusion in 37 of the 52 nodules, whereas it decreased in the remaining 15 nodules. Yoshimatsu et al [31] showed that the degree of tumor enhanceme nt on selective CT during hepatic angiography (CTHA) increased after balloon occlusion in 3 of the 27 nodules, while it decreased in 11 nodules. Asayama et al [32] also reported that 15 of the 35 nodules showed decreased enhancement or perfusion defects on CTHA with balloon occlusion. While the percentage of decreased tumor enhancement varied markedly among those studies, it remained a negative predictive factor for a dense LE accumulation [30, 31] and shortterm therapeutic eff ect [32] . It can be presumed that the blood flow from the occluded artery reduced and the blood flow from the collateral arteries relatively increased [31, 32] . In relation to this, a discrepancy was noted between the tumor enhancement on selective CTHA with balloon occlusion and a dense LE accumulation after BTACE, which was higher than the tumor enhancement grade [31] . Although CBCT [3335] and CTHA [36, 37] are well known to be useful tools for identifying the tumorfeeding arteries, evaluating the embolized area and avoiding nontargeted embolizati on, the same findings were reported in selective C TACE [38] . A validation study will be needed to confirm whether or not a decreased tumor enhancement after balloon occlusion can predict the short and longterm therapeutic effects.
With regard to the analysis of CT findings during arterial portography (CTAP), the reduction in size of the tumorous portal perfusion defects on CTAP with ballo on occlusion was observed in 90% (18/20) of nodules. Its mean size significantly decreased from 21.9 to 19.1 mm in diameter (P = 0.0001). No decrease in the tumorous portal perfusion defect area significantly influenced the poor dense LE accumulation in the tu mor [31] . The authors speculated that the decrease in the BOASP enabled the pressure gradient from the hepatic artery to the portal vein to also decrease, thus resulting in a relative increase in the blood flow from the portal vein in the surrounding tumor [31] . In other words, no change in the size of the tumorous portal perfusion defect may indicate no decrease in the BOASP [31] . To fa cilitate our understanding of the mechanism of BTACE, we summarize the main findings mentioned above and present them in a schematic illustration in Figure 4 .
THERAPEUTIC EFFECT OF B-TACE
Short-term therapeutic effect and local recurrence rate
In many previous studies, the short-term therapeutic effect of BTACE was evaluated mainly by the Respo nse Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan [39] . The treatment effect (TE) was determined by the ra diological findings 13 mo after BTACE treatment and defined as follows: TE4, tumor necrosis of 100% or 100% reduction; TE3, tumor necrosis of 50%100% or 50%100% reduction in tumor size; TE1, tumor enlar gement of > 50% regardless of necrosis; TE2, effect other than TE3 or TE1 [39] . According to previous repo rts [13, 15, 32, 40, 41] , the rate of TE4 of targeted HCC nodules treated with BTACE was 8.6%89.3%, and that of TE3 was 8.5%48.6%, with a response rate of 56.3%100%.
Kawamura et al [40] showed that the presence of po rtal vein visualization during treatment was associated with an objective response, which is consistent with findings of the study reported by Miyayama et al [42] . However, the evaluation of the therapeutic effect of BTACE in these studies [13, 15, 32, 40, 41] was limited to only targeted lesions and did not include the appearance of new lesions. According to a study [43] evaluated based on the overall response, including target lesions, nontarg et lesions and the appearance of new lesion, 35 patients (53.0%) experienced complete response (CR), 7 patie nts (10.6%) partial response (PR), 13 patients (19.7%) stable disease, and 11 patients (16.7%) progressive di sease. The rate of a response rate and a disease control rate were 63.6% and 83.3%, respectively. Furthermore, a multivariate analysis showed that a solitary tumor and serum α-fetoprotein level were significantly relevant to the tumor response [43] . Regarding the analysis of the local recurrence rate, Ishikawa et al [44] showed that the median recurrence time and the local recurrence rate at 6 mo and 12 mo were 9 mo and 11.1% and 26.2%. The authors further revealed that only the CT value just after BTACE was significantly relevant to local recurrence in a multivariate analysis [44] . CBCT was also deemed useful as a sub stitute for conventional CT to evaluate the degree of dense LE accumulation quantitatively in targeted HCC nodules [45] . Irie et al [15] also showed that the control rates of primary nodule treated by BTACE at 1, 3 and 5 years were 92.4%, 69.9% and 69.9%, respectively. However, these were retrospective studies, and the nu mber of nodules per patient was small (many patients had solitary nodules). The results should therefore be interpreted with caution when extrapolating to HCC pa tients with more nodules. A summary of the previous studies is shown in Table 1 . A prospective validation st udy is warranted.
Suitable anticancer agents
The anticancer agents that have been used in BTACE are as follows: Miriplatin [13, 14, 31, 32, 40, 41, 44] , which was the most commonly used; cisplatin [29, 31] ; epirubicin [20] and a mixture of doxorubicin hydrochloride and mitomycin [10, 15] . Miriplatin, which is a lipophilic platinum complex [18, 19] , has been used in CTACE [46] . A retrospective study [47] showed that the local recurrence rate was significantly higher after superselective TACE with miriplatin than with epirubucin and mitomycin. This may be attributed to its high viscosity, and warmed miriplatin may reduce its viscosity, possibly overcoming its disadvantages and increasing its therapeutic effect [48, 49] . Therefore, BTACE with warmed miriplatin may exert a better therapeutic effect than that with miriplatin at room temperature. In this connection, arterial vascular damage is less severe in patients treated with miriplatin than in those trea ted with epirubicin [50] . Although no RCT has compared antitumor agents, miriplatin might be suitable as an anticancer agent in BTACE. Further studies should be conducted.
Comparing the effectiveness of B-TACE and C-TACE
Reliable data on the comparative efficacy between BTACE and CTACE are still lacking, with only four ret rospective studies reported. Arai et al [13] reported that the targeted therapeutic effect of BTACE with miriplat in was better than that of CTACE, and the mean total dose of miriplatin in BTACE was higher than that of C-TACE. They presumed that inflating the microballoon catheter decreased the arterial pressure proximal of the tip of the catheter and blocked the backflow of miriplatin, resulting in a higher total dose of miriplatin and a better therapeutic effect on targeted nodules than with CTACE. Ogawa et al [14] also reported that TE4 was observed in 29 patients (49.2%) treated with BTACE and in 10 patients (27%) treated with CTACE, indicating that local efficacy of B-TACE was significantly better than that of C-TACE. Irie et al [15] reported that the short-term treatment effect based on RECICL criteria was significantly better in BTACE group than that in the CTACE group, and the tumor control rates of the targeted nodule were significantly improved in the BTACE group compared to CTACE group. However, Maruyama et al [20] reported that the local control ra te in BTACE group were not significantly better than in the CTACE group. The major cause of this was the lack of a significant difference between the two groups In this situation, we might observe increased tumor enhancement on selective computed tomography during hepatic angiography (CTHA) after balloon occlusion. A remarkable reduction in the BOASP is thought to allow us to inject the lipiodol emulsion (LE) under higher pressure, leading to the denser LE accumulation in targeted tumors. The BOASP after the injection of LE and gelatin particles is significantly higher than that before treatment; C and D: When the ICAs are thick, the BOASP is expected to be mildly reduced or unchanged because of the adequate blood flow from a thick ICA. In this situation, we might observe decreased tumor enhancement on CTHA after balloon occlusion. We would probably inject the LE under lower pressure in such a situation, thereby achieving a lessdense LE accumulation. 
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in the analysis of the LE ratio. The LE ratio, which was calculated as the ratio of the LE concentration in the targeted tumor to that in the surrounding embolized noncancerous area, was considered to be an indicat or of the selectivity of the LE accumulation in HCC [10] . Alternatively, this finding may have been observed because most patients received BTACE treatment at the lobar or segmental level, resulting in a lessmarked decrease in the BOASP and therefore a lessmarked th erapeutic effect [26] . More largescale prospective studies are warranted.
INDICATIONS OF B-TACE
Since no definitive indications of B-TACE have been established to date, we explored potential factors and conditions supporting the performance of BTACE. Su mmarizing the findings of the previous studies mentioned above, the following factors and conditions are known to be related to a dense LE accumulation in targeted HCC nodules and the therapeutic effect of BTACE: a BOASP ≥ 64 mmHg [10] ; microballoon occlusion at A1, A4, A8, anterior segment artery, RHA or LHA [26] ; decr eased tumor enhancement on CBCT and CTHA [3032] ; no decrease in the tumorous portal perfusion defect on CTAP [31] ; tumor location on the subcapsular portion [40] ; successful subsegmental feeding artery embolization [40] ; the presence of portal vein visualization [40] ; a high CT value just after BTACE [44] ; solitary tumor [43] and a low serum αfetoprotein level [43] . Based on studies [1315] sh owing that patients with fewer tumor nodules experi enced a better therapeutic effect with BTACE than with CTACE, BTACE might be a better indication than CTACE in patients with fewer tumor nodules. Prospective va lidation studies are needed to clarify the indications of BTACE. The contraindications of BTACE were thought to be almost the same as those for CTACE treatment: Child Pugh class C, no tumor thrombosis in the first branch or main portal vein, extrahepatic metastasis, refractory ascites, hepatic encephalopathy, presence of high-flow arterioportal or arteriovenous shunts, and allergy to co ntrast medium.
OVERALL SURVIVAL OF B-TACE
Hatanaka et al [43] reported that the survival rates at 1, 3 and 5 years in patients after BTACE were 76.8%, 57.3% and 46.7%, respectively, and the median sur vival time was 902 d. They also revealed that a serum albumin level ≥ 3.4 g/dL and an overall response of CR+PR were favorable prognostic factors in a multiv ariate analysis [43] . Serum albumin is one of the most wellknown prognostic factors for patients with HCC and has been adopted and integrated into several staging systems, including the BCLC staging system [3] , Cancer of the Liver Italian Program (CLIP) score [51] and Japan
Integrated Staging score (JIS score) [52] . According to previous studies of TACE [53, 54] , the overall response has been reported to be an independent factor affecting for the survival of HCC patients. Although the findings reported by Hatanaka et al [43] were consistent with th ose of previous studies [53, 54] , the results were based on a singlearm and singleinstitution study. Additional vali dation studies are therefore warranted.
One problem that remains to be solved is whether or not BTACE improves the overall survival compared to other TACE treatments. Unfortunately, no RCTs have compared BTACE with other TACE treatments, such as CTACE and DEBTACE, and only one historical control study [15] with patients who had solitary or two nodules has been reported. However, while it was small in scale, that study found that B-TACE was a significant factor predicting for the overall survival in a multivariate an alysis [15] . A largescale prospective study is therefore warranted.
COMPLICATIONS OF B-TACE
According to previous reports [13, 20, 43, 44] and vagovagal reflex in 12%, while a grade 3/4 fever was reported as a complication in 0%6% of cases, elevated total bilirubin in 0%6.1%, elevated ALT in 9.1%18%, leukocytopenia in 0%12.1% and thrombocytopenia in 7.6%-12.2%. In an analysis comparing the adverse events of BTACE with those of CTACE, the rate of in creased levels of ALT was significantly higher in the B TACE group, with no significant differences in the clinical symptoms or other laboratory data between the two groups [13, 20] . Hatanaka et al [43] reported no mortalities, but the development of biloma requiring percutaneous trans hepatic biliary drainage after BTACE was observed in 1 patient (1.5%) who had intrahepatic dilation on preoperative CT. Maruyama et al [20] reported that liver abscess was observed in 3 patients (6%), and liver inf arction was observed in 1 patient (2%), with bile duct dilation indicated as a significant predictive factor in a multivariate analysis. Careful consideration must be giv en to perform the BTACE for the patients with bile duct dilation [43] . Largescale validation studies are therefore needed to confirm these findings.
CONCLUSION
BTACE represents a feasible and promising therapy for the treatment of HCC patients, especially those with few nodules. Although no definitive indication of B-TACE in the common clinical practice has yet been established, leaving the decision to perform this procedure up to
